Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 9/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.48 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SI | P14410 | 1/20 | 0.47 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30515646 | 0.98 | HDAC6 (0.57) | HDAC6PPARASMN1; SMN2NPSR1LOXL2 | |
| SCHEMBL3643594 | 0.98 | HDAC6 (0.57) | HDAC6PPARASMN1; SMN2NPSR1LOXL2 | |
| SCHEMBL3641915 | 0.85 | PPARA (0.57) | PPARASMN1; SMN2GAA | |
| SCHEMBL11228986 | 0.85 | SMN1; SMN2 (0.54) | HDAC6PPARASMN1; SMN2NPSR1LOXL2 | |
| SCHEMBL24962530 | 0.83 | SMN1; SMN2 (0.57) | HDAC6PPARASMN1; SMN2NPSR1LOXL2 | |
| SCHEMBL30209129 | 0.83 | SMN1; SMN2 (0.57) | HDAC6PPARASMN1; SMN2NPSR1LOXL2 | |
| SCHEMBL3711953 | 0.83 | SMN1; SMN2 (0.53) | HDAC6PPARASMN1; SMN2NPSR1LOXL2 | |
| SCHEMBL27714125 | 0.83 | PPARA (0.56) | PPARASMN1; SMN2GAA | |
| SCHEMBL3621187 | 0.82 | SMN1; SMN2 (0.51) | HDAC6PPARASMN1; SMN2NPSR1LOXL2 | |
| SCHEMBL28258783 | 0.81 | PPARA (0.54) | HDAC6PPARASMN1; SMN2NPSR1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| CN-1623537-A | Biaryl sulfonamides and its using method | WYETH CORP (US) | 2005-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | HDAC6 234/4885PPARA 2386/4885SMN1; SMN2 3220/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | HDAC6 234/4885PPARA 2386/4885SMN1; SMN2 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.